A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (NCT04404660)
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (ALL).
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- City of Hope National Medical Center — Duarte, California
- University of California San Diego Health (UCSD) — La Jolla, California
- University of California Davis (UC Davis) — Sacramento, California
- University of California San Francisco (UCSF) — San Francisco, California
- Colorado Blood Cancer Institute (CBCI) — Denver, Colorado
- University of Miami — Miami, Florida
- H Lee Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- University of Kansas — Kansas City, Kansas
- University of Maryland Medical Center — Baltimore, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic — Rochester, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- University of Nebraska — Omaha, Nebraska
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of Rochester — Rochester, New York
- Cleveland Clinic — Cleveland, Ohio
- TriStar Centennial Medical Center (SCRI) — Nashville, Tennessee
- Baylor Scott & White Research Institute — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- TTI-Methodist (Texas Transplant Institute) (SCRI) — San Antonio, Texas
- The Medical College of Wisconsin — Milwaukee, Wisconsin
- Fundacio' Hospital Universitari Vall d'Hebron — Barcelona,
- Hospital Universitario Virgen del Rocío — Seville,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Explore by condition: All Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.